Zinc and Iron Homeostasis: Target-Based Drug Screening as New Route for Antifungal Drug Development

被引:19
|
作者
Simm, Claudia [1 ,2 ]
May, Robin C. [1 ]
机构
[1] Univ Birmingham, Inst Microbiol & Infect, Sch Biosci, Birmingham, W Midlands, England
[2] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia
基金
欧洲研究理事会;
关键词
Candida; antifungals; high throughput drug screening; zinc homeostasis; iron homeostasis; artemisinin; pyrvinium pamoate; CANDIDA; VIRULENCE; COMMENSALISM; ARTEMISININS; ASPERGILLUS; MECHANISMS; GROWTH; ROLES; AGENT;
D O I
10.3389/fcimb.2019.00181
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The incidence of fungal diseases is on the rise and the number of fatalities is still unacceptably high. While advances into antifungal drug development have been made there remains an urgent need to develop novel antifungal agents targeting as-yet unexploited pathways, such as metal ion homeostasis. Here we report such an approach by developing a metal sensor screen in the opportunistic human fungal pathogen Candida albicans. Using this reporter strain, we screened a library of 1,200 compounds and discovered several active compounds not previously described as chemical entities with antifungal properties. Two of these, artemisinin and pyrvinium pamoate, have been further characterized and their interference with metal homeostasis and potential as novel antifungal compounds validated. Lastly, we demonstrate that the same strain can be used to report on intracellular conditions within host phagocytes, paving the way toward the development of novel screening platforms that could identify compounds with the potential to perturb ion homeostasis of the pathogen specifically within host cells.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Target-based drug discovery for β-globin disorders: drug target prediction using quantitative modeling with hybrid functional Petri nets
    Mehraei, Mani
    Bashirov, Rza
    Tuzmen, Sukru
    JOURNAL OF BIOINFORMATICS AND COMPUTATIONAL BIOLOGY, 2016, 14 (05)
  • [42] Highly drug/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibody
    Fu, Rongrong
    Xu, Jin
    Guo, Qingcheng
    Liu, Tao
    Su, Xinyi
    Xu, Mengjiao
    Zhao, Xiang
    Wang, Fugui
    Ji, Lusha
    Qian, Weizhu
    Hou, Sheng
    Li, Jun
    Zhang, Dapeng
    Guo, Huaizu
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2024, 241
  • [43] Molecular modeling and virtual screening to identify new antifungal compounds against the drug target thioredoxin reductase
    Abadio, A. K.
    Kioshima, E. S.
    Martins, N.
    Maigret, B.
    Felipe, M.
    FEBS JOURNAL, 2014, 281 : 146 - 146
  • [45] Pocket2Drug: An Encoder-Decoder Deep Neural Network for the Target-Based Drug Design
    Shi, Wentao
    Singha, Manali
    Srivastava, Gopal
    Pu, Limeng
    Ramanujam, J.
    Brylinski, Michal
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [46] Phospholipid remodeling as a target for antifungal drug development against Candida albicans
    Algahmi, Amal M.
    Ayyash, Mariam K.
    Oelkers, Peter
    FASEB JOURNAL, 2013, 27
  • [47] Advances in Key Drug Target Identification and New Drug Development for Tuberculosis
    Mi, Jie
    Gong, Wenping
    Wu, Xueqiong
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [48] Bromodomains: a new target class for drug development
    Andrea G. Cochran
    Andrew R. Conery
    Robert J. Sims
    Nature Reviews Drug Discovery, 2019, 18 : 609 - 628
  • [49] SICKNESS BEHAVIOR AS A NEW TARGET FOR DRUG DEVELOPMENT
    KENT, S
    BLUTHE, RM
    KELLEY, KW
    DANTZER, R
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (01) : 24 - 28
  • [50] Bromodomains: a new target class for drug development
    Cochran, Andrea G.
    Conery, Andrew R.
    Sims, Robert J., III
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (08) : 609 - 628